ASS1 and neoplasm: In summary, our data implicate a novel macrophage-mediated mechanism of resistance to ADI-PEG20 in ASS1-negative MPM, namely the delivery of argininosuccinate by the macrophage-rich tumor microenvironment under cytokine control.